Loading cancer entity…
Loading cancer entity…
Clinical trials
805 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06455358 | 61Cu-NODAGA-LM3 PET/CT for the Detection of Neuroendocrine Tumors (COPPER PET in NET) | recruiting | Phase 1 / Phase 2 | 27 | University Hospital, Basel, SwitzerlandOTHER | 1 | May 30, 2025 | clinicaltrials |
| NCT04579757 | Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 87 | HutchmedINDUSTRY | 1 | May 8, 2025 | clinicaltrials |
| NCT06456723 |
| Evaluation of [18F]Fluoroethyl Triazole Labelled [Tyr3]-Octreotate Analogues for the Imaging of Neuroendocrine Tumours.(FETONET) |
| completed |
| Phase 1 / Phase 2 |
| 56 |
| Imperial College LondonOTHER |
| 0 |
| May 1, 2025 |
| clinicaltrials |
| NCT05167071 | HBM4003 Combine With Toripalimab in Patients With Advanced NEN and Other Solid Tumors Study | active not recruiting | Phase 1 | 53 | Harbour BioMed (Guangzhou) Co. Ltd.INDUSTRY | 1 | Apr 27, 2025 | clinicaltrials |
| NCT04893759 | A Study of Pelcitoclax (APG-1252) in Patients With Neuroendocrine Tumors | terminated | Phase 1 | 2 | Ascentage Pharma Group Inc.INDUSTRY | 1 | Apr 17, 2025 | clinicaltrials |
| NCT06056362 | Comparison of Al18F-NOTA-LM3 With 68Ga-DOTATATE and 68Ga-NODAGA-LM3 PET/CT in Patients With Well-differentiated Neuroendocrine Tumors | recruiting | Phase 1 / Phase 2 | 80 | Peking Union Medical College HospitalOTHER | 1 | Apr 2, 2025 | clinicaltrials |
| NCT02348749 | 18F-MFBG Imaging for Evaluation of Neuroendocrine Malignancies | completed | Phase 1 / Phase 2 | 48 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Mar 19, 2025 | clinicaltrials |
| NCT02464007 | Study of rSIFN-co for Patients With Advanced Solid Tumors | terminated | Phase 1 | 7 | Sichuan Huiyang Life Science and Technology CorporationINDUSTRY | 1 | Feb 25, 2025 | clinicaltrials |
| NCT05053854 | PARP Inhibitor With 177Lu-DOTA-Octreotate PRRT in Patients With Neuroendocrine Tumours(PARLuNET) | recruiting | Phase 1 | 24 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | Feb 20, 2025 | clinicaltrials |
| NCT02736500 | Peptide Receptor Radionuclide Therapy With 177Lu-Dotatate Associated With Metronomic Capecitabine In Patients Affected By Aggressive Gastro-Etero-Pancreatic Neuroendocrine Tumors(LuX) | completed | Phase 1 / Phase 2 | 39 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSOTHER | 1 | Jan 13, 2025 | clinicaltrials |
| NCT02749331 | Study of Recombinant Adenovirus AdVince in Patients With Neuroendocrine Tumors; Safety and Efficacy(RADNET) | active not recruiting | Phase 1 / Phase 2 | 35 | Uppsala UniversityOTHER | 1 | Dec 3, 2024 | clinicaltrials |
| NCT05199272 | A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies | active not recruiting | Phase 1 / Phase 2 | 141 | 23andMe, Inc.INDUSTRY | 2 | Nov 15, 2024 | clinicaltrials |
| NCT05610826 | Preoperative PRRT Versus Surgical Cytoreduction in Metastatic Pancreatic Neuroendocrine Tumors to the Liver | withdrawn | Phase 1 / Phase 2 | 0 | University of ChicagoOTHER | 1 | Oct 26, 2024 | clinicaltrials |
| NCT05176665 | EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers | unknown | Phase 1 / Phase 2 | 152 | Shanghai EpimAb Biotherapeutics Co., Ltd.INDUSTRY | 2 | Aug 26, 2024 | clinicaltrials |
| NCT00655655 | Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors | completed | Phase 1 | 96 | Mayo ClinicOTHER | 1 | Aug 21, 2024 | clinicaltrials |
| NCT02021604 | Fluorodopa F 18 in Congenital Hyperinsulinism and Insulinoma | recruiting | Phase 1 | 250 | Cook Children's Health Care SystemOTHER | 1 | Jul 16, 2024 | clinicaltrials |
| NCT02110563 | Phase I, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Solid Tumors, Multiple Myeloma, or Lymphoma | terminated | Phase 1 | 50 | Dicerna Pharmaceuticals, Inc., a Novo Nordisk companyINDUSTRY | 1 | Jul 11, 2024 | clinicaltrials |
| NCT03038308 | Treatment of Hyperprolactinemia With the Non-ergoline Dopamine Agonist Ropinirole | completed | Phase 1 / Phase 2 | 16 | Columbia UniversityOTHER | 1 | Jun 4, 2024 | clinicaltrials |
| NCT04614766 | A Clinical Trial Evaluating the Safety of Combining Lutathera(R) and Azedra(R) to Treat Mid-gut Neuroendocrine Tumors(SPORE-3) | withdrawn | Phase 1 / Phase 2 | 0 | David BushnellOTHER | 1 | Apr 29, 2024 | clinicaltrials |
| NCT05475210 | 177Lu-DOTA-EB-TATE in Adult Patients With Advanced, Well- Differentiated Neuroendocrine Tumors | unknown | Phase 1 | 9 | Molecular Targeting Technologies, Inc.INDUSTRY | 1 | Mar 13, 2024 | clinicaltrials |
| NCT06155994 | 68Ga-DOTA-MGS5 PET/CT in Patients With Advanced Neuroendocrine Tumours | completed | Phase 1 / Phase 2 | 12 | Medical University InnsbruckOTHER | 1 | Dec 5, 2023 | clinicaltrials |
| NCT04602117 | ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer | withdrawn | Phase 1 | 0 | QuantumLeap Healthcare CollaborativeOTHER | 1 | Nov 18, 2023 | clinicaltrials |
| NCT04979611 | The Clinical Application of 68Ga-NOTA-exendin-4 PET/CT in Detecting Insulinoma | unknown | Phase 1 | 60 | First Affiliated Hospital of Fujian Medical UniversityOTHER | 1 | Sep 21, 2023 | clinicaltrials |
| NCT02592707 | Study to Evaluate the Safety and Preliminary Efficacy of 177Lu-OPS201 in NETs | terminated | Phase 1 / Phase 2 | 40 | IpsenINDUSTRY | 8 | Jul 19, 2023 | clinicaltrials |
| NCT03043664 | Study of Pembrolizumab With Lanreotide Depot for Gastroenteropancreatic Neuroendocrine Tumors(PLANET) | completed | Phase 1 / Phase 2 | 22 | Duke UniversityOTHER | 1 | Jun 29, 2023 | clinicaltrials |
| NCT04212793 | Detection of PitNET Tissue During TSS Using Bevacizumab-800CW(DEPARTURE) | completed | Phase 1 | 20 | University Medical Center GroningenOTHER | 1 | Apr 14, 2023 | clinicaltrials |
| NCT05800106 | A Bioequivalence Study of Sunitinib Malate Capsules. | completed | Phase 1 | 24 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Apr 10, 2023 | clinicaltrials |
| NCT02943733 | Safety of TAS-102 in Combination With Temozolomide for Metastatic Pancreatic NETs | terminated | Phase 1 | 18 | University of Wisconsin, MadisonOTHER | 1 | Sep 23, 2022 | clinicaltrials |
| NCT03478358 | Treatment Using 177Lu-DOTA-EB-TATE in Patients With Advanced Neuroendocrine Tumors | unknown | Phase 1 | 60 | Peking Union Medical College HospitalOTHER | 1 | Aug 31, 2022 | clinicaltrials |
| NCT04258592 | 18F-MFBG PET Imaging of the Norepinephrine Transporter in Neural Crest and Neuroendocrine Tumors | terminated | Phase 1 | 6 | Universitaire Ziekenhuizen KU LeuvenOTHER | 1 | Aug 12, 2022 | clinicaltrials |
| NCT03411915 | A Study of XmAb®18087 in Subjects With NET and GIST | completed | Phase 1 | 62 | Xencor, Inc.INDUSTRY | 1 | May 10, 2022 | clinicaltrials |
| NCT03147768 | Laser Tissue Welding - Distal Pancreatectomy Sealing Study(LTW) | completed | Phase 1 | 11 | Laser Tissue Welding, Inc.INDUSTRY | 1 | Apr 6, 2022 | clinicaltrials |
| NCT01218555 | Study of Everolimus (RAD001) in Combination With Lenalidomide | completed | Phase 1 | 44 | Emory UniversityOTHER | 1 | Jan 27, 2022 | clinicaltrials |
| NCT04318561 | Gallium-68 Labeled LM3 PET/CT in Neuroendocrine Tumors(PET) | completed | Phase 1 / Phase 2 | 40 | Peking Union Medical College HospitalOTHER | 1 | Dec 21, 2021 | clinicaltrials |
| NCT02936323 | PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Cancers | completed | Phase 1 / Phase 2 | 89 | Tarveda TherapeuticsINDUSTRY | 2 | Dec 14, 2021 | clinicaltrials |
| NCT01465659 | Temozolomide and Pazopanib Hydrochloride in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors That Cannot Be Removed By Surgery | completed | Phase 1 / Phase 2 | 29 | Northwestern UniversityOTHER | 1 | Aug 5, 2021 | clinicaltrials |
| NCT01619865 | Safety of 68Ga-DOTA-tyr3-Octreotide PET in Diagnosis of Solid Tumors(GA-68) | completed | Phase 1 / Phase 2 | 223 | Sue O'DorisioOTHER | 1 | Jul 27, 2021 | clinicaltrials |
| NCT03189953 | 68Ga-NODAGA-exendin-4 PET/CT for Diagnostic Imaging in AHH(GLP-1-AHH) | completed | Phase 1 / Phase 2 | 56 | Radboud University Medical CenterOTHER | 0 | Jun 16, 2021 | clinicaltrials |
| NCT03923257 | Dosimetry Guided PRRT With 177Lu-DOTATATE in Children and Adolescents | withdrawn | Phase 1 / Phase 2 | 0 | Sue O'DorisioOTHER | 1 | Jun 8, 2021 | clinicaltrials |
| NCT00446082 | Study of Pasireotide Long Acting Release (LAR) Injection in Patients With Acromegaly and Patients With Carcinoid Disease | completed | Phase 1 | 85 | Novartis PharmaceuticalsINDUSTRY | 6 | Dec 21, 2020 | clinicaltrials |
| NCT01263353 | Safety and Tolerability of Pasireotide LAR in Combination With Everolimus in Advanced Metastatic NETs(COOPERATE-1) | completed | Phase 1 | 36 | Novartis PharmaceuticalsINDUSTRY | 1 | Dec 21, 2020 | clinicaltrials |
| NCT01364415 | Dose Escalation Study of Pasireotide (SOM230) in Patients With Advanced Neuroendocrine Tumors (NETs) | completed | Phase 1 | 29 | Novartis PharmaceuticalsINDUSTRY | 1 | Dec 21, 2020 | clinicaltrials |
| NCT02355535 | Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies - Component 1 | completed | Phase 1 | 48 | Vanquish Oncology, Inc.INDUSTRY | 1 | Sep 24, 2020 | clinicaltrials |
| NCT03883776 | Al18F-NOTA-octreotide PET Imaging of the Somatostatin Receptor in Neuroendocrine Tumors | completed | Phase 1 | 12 | Universitaire Ziekenhuizen KU LeuvenOTHER | 1 | Sep 9, 2020 | clinicaltrials |
| NCT03881306 | DEBOXA for Inoperable NET Liver Metastases | unknown | Phase 1 / Phase 2 | 60 | Xiangya Hospital of Central South UniversityOTHER | 1 | Aug 20, 2020 | clinicaltrials |
| NCT00576680 | RAD001 and Temozolomide in Patients With Advanced Pancreatic Neuroendocrine Tumors | completed | Phase 1 / Phase 2 | 43 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 9, 2020 | clinicaltrials |
| NCT01970540 | Study Escalating Doses of PM01183 in Combination With Fixed Doxorubicin in Patients With Specific Advanced Unresectable Solid Tumors | completed | Phase 1 | 122 | PharmaMarINDUSTRY | 2 | Mar 9, 2020 | clinicaltrials |
| NCT01165658 | Study of Hypofractionated Proton Radiation Therapy in Thoracic Malignancies | terminated | Phase 1 | 30 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 2, 2020 | clinicaltrials |
| NCT02177773 | GA-68 DOTA-TOC of Somatostatin Positive Malignancies(DOTA-TOC) | terminated | Phase 1 / Phase 2 | 300 | University of California, San FranciscoOTHER | 1 | Nov 12, 2019 | clinicaltrials |
| NCT02162446 | 68Ga-OPS202 Study for Diagnostic Imaging of GEP NET | completed | Phase 1 / Phase 2 | 12 | IpsenINDUSTRY | 1 | Oct 2, 2019 | clinicaltrials |
Data updated 22 days agoSource updated May 30, 2025source: clinicaltrials